MassChallenge Switzerland & UK has unveiled its 2026 accelerator cohort, selecting some of the most promising early-stage startups from a highly competitive global applicant pool. The cohort spans a range of sectors—including health, life sciences, climate, and deep technology—and will gain access to mentorship, industry partners, investors, and commercialization support designed to accelerate growth and impact.Among the companies selected is CABHI-supported Neuropeutics, whose inclusion highlights the growing momentum behind innovations addressing brain health and neurological conditions.
The announcement underscores the strength of the global innovation ecosystem and the increasing attention being directed toward health technologies with the potential to deliver meaningful societal impact. Read on to learn more about the 2026 cohort and how startups like Neuropeutics are leveraging accelerator programmes to scale breakthrough innovations.
